论文信息 - The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. - 字舞流文

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.

T. Habermann | S. Ansell | H. Tun | C. Reeder | S. Markovic | T. Witzig | B. Laplant | Mamta Gupta | G. Nowakowski | D. Inwards | W. Macon | J. Colgan | I. Micallef | L. Porrata | P. Johnston | J. Han | M. Stenson | G. Nowakowski